$MGNX
MACROGENICS INC Stock $mgnx

$mgnx Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000112534523000076 Filed on May 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q4
Revenue	$13.14M	$24.50M	$73.10M
YoY Change	-49.49%	120.66%	416.71%
Cost Of Revenue	$258.0K	$113.0K	$1.791M
YoY Change	43.33%	135.42%	89.12%
Gross Profit	$12.88M	$24.38M	$71.31M
YoY Change	-50.14%	120.6%	440.21%
Gross Profit Margin	98.04%	99.54%	97.55%
Selling, General & Admin	$13.69M	$13.53M	$13.67M
YoY Change	0.17%	-16.77%	-12.26%
% of Gross Profit	106.32%	55.48%	19.17%
Research & Development	$43.23M	$45.87M	$45.65M
YoY Change	-16.46%	-25.34%	-18.26%
% of Gross Profit	335.68%	188.13%	64.02%
Depreciation & Amortization	$2.812M	$2.983M	$3.231M
YoY Change	-2.26%	2.4%	9.45%
% of Gross Profit	21.84%	12.23%	4.53%
Operating Expenses	$43.23M	$45.87M	$59.33M
YoY Change	-16.46%	-25.34%	-16.95%
Operating Profit	-$44.96M	-$38.43M	$11.98M
YoY Change	7.54%	-42.34%	-120.58%
Interest Expense	$774.0K	-$656.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net	$2.275M	$1.073M	$819.0K
YoY Change	351.39%	450.26%	282.71%
Pretax Income	$57.47M	-$38.01M	$12.80M
YoY Change	-239.14%	-42.79%	-122.06%
Income Tax
% Of Pretax Income
Net Earnings	$57.47M	-$38.01M	$12.80M
YoY Change	-239.14%	-42.79%	-122.06%
Net Earnings / Revenue	437.49%	-155.16%	17.51%
Basic Earnings Per Share	$0.93	-$0.61
Diluted Earnings Per Share	$0.92	-$0.61	$0.21
COMMON SHARES
Basic Shares Outstanding	61.84M shares	61.84M shares	61.48M shares
Diluted Shares Outstanding	62.26M shares	61.81M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$240.3M	$241.7M	$154.3M
YoY Change	79.71%	31.34%	-36.64%
Cash & Equivalents	$108.8M	$224.3M	$108.9M
Short-Term Investments	$131.6M	$17.39M	$45.46M
Other Short-Term Assets	$6.475M	$9.718M	$10.16M
YoY Change	-48.44%	-33.95%	-52.0%
Inventory	$1.443M	$1.409M	$1.451M
Prepaid Expenses			$10.16M
Receivables	$6.410M	$36.16M	$56.22M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$254.7M	$288.9M	$222.2M
YoY Change	51.92%	32.42%	-20.53%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.09M	$26.78M	$29.58M
YoY Change	-29.19%	-25.67%	-21.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.386M	$1.378M	$1.378M
YoY Change	-91.54%	-91.99%	-92.35%
Total Long-Term Assets	$50.98M	$54.56M	$58.29M
YoY Change	1.13%	2.46%	4.67%
TOTAL ASSETS
Total Short-Term Assets	$254.7M	$288.9M	$222.2M
Total Long-Term Assets	$50.98M	$54.56M	$58.29M
Total Assets	$305.7M	$343.5M	$280.5M
YoY Change	40.18%	26.54%	-16.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.795M	$3.759M	$4.899M
YoY Change	45.46%	0.75%	-68.39%
Accrued Expenses	$27.53M	$28.19M	$29.00M
YoY Change	-13.33%	-14.5%	-14.09%
Deferred Revenue	$9.671M	$9.249M	$9.988M
YoY Change	-16.38%	-63.82%	-51.62%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$45.16M	$45.61M	$48.61M
YoY Change	-11.25%	-32.02%	-34.82%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$258.0K	$258.0K	$258.0K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Liabilities	$258.0K	$258.0K	$258.0K
YoY Change	0.0%	0.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$45.16M	$45.61M	$48.61M
Total Long-Term Liabilities	$258.0K	$258.0K	$258.0K
Total Liabilities	$134.1M	$234.2M	$138.5M
YoY Change	77.48%	151.24%	44.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.074B	-$1.132B	-$1.094B
YoY Change	-0.69%	8.78%	12.3%
Common Stock	$1.246B	$1.241B	$1.236B
YoY Change	1.74%	1.81%	1.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$171.5M	$109.3M	$142.0M
YoY Change
Total Liabilities & Shareholders Equity	$305.7M	$343.5M	$280.5M
YoY Change	40.18%	26.54%	-16.34%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	$57.47M	-$38.01M	$12.80M
YoY Change	-239.14%	-42.79%	-122.06%
Depreciation, Depletion And Amortization	$2.812M	$2.983M	$3.231M
YoY Change	-2.26%	2.4%	9.45%
Cash From Operating Activities	-$2.089M	-$12.83M	$29.32M
YoY Change	-95.75%	-77.76%	-153.99%
INVESTING ACTIVITIES
Capital Expenditures	$286.0K	$359.0K	$393.0K
YoY Change	-128.29%	-74.63%	-128.58%
Acquisitions
YoY Change
Other Investing Activities	-$113.2M	$28.45M	-$5.395M
YoY Change	-570.64%	-266.72%	-55.7%
Cash From Investing Activities	-$113.5M	$28.10M	-$5.788M
YoY Change	-592.54%	-252.01%	-57.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	59.00K	$100.1M	1.359M
YoY Change	-77.57%	270489.19%	69.88%
NET CHANGE
Cash From Operating Activities	-2.089M	-$12.83M	29.32M
Cash From Investing Activities	-113.5M	$28.10M	-5.788M
Cash From Financing Activities	59.00K	$100.1M	1.359M
Net Change In Cash	-115.5M	$115.4M	24.89M
YoY Change	346.68%	-251.53%	-137.12%
FREE CASH FLOW
Cash From Operating Activities	-$2.089M	-$12.83M	$29.32M
Capital Expenditures	$286.0K	$359.0K	$393.0K
Free Cash Flow	-$2.375M	-$13.19M	$28.93M
YoY Change	-95.07%	-77.68%	-154.65%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001125345
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-36112
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	MACROGENICS, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	06-1591613
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	9704 Medical Center Drive
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Rockville
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20850
CY2023Q1	dei	City Area Code CityAreaCode	301
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	251-5172
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	MGNX
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	61838893	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	224264000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	108884000	usd
CY2023Q1	us-gaap	Investments Investments	17392000	usd
CY2022Q4	us-gaap	Investments Investments	45462000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	36160000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	56222000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	1409000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1451000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9718000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10161000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	288943000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	222180000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26783000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	29575000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26394000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	27335000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1378000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1378000	usd
CY2023Q1	us-gaap	Assets Assets	343498000	usd
CY2022Q4	us-gaap	Assets Assets	280468000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3759000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4899000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28188000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28998000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	9249000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	9988000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4418000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4726000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	45614000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	48611000	usd
CY2023Q1	mgnx	Liability Related To Future Royalties LiabilityRelatedToFutureRoyalties	100222000	usd
CY2022Q4	mgnx	Liability Related To Future Royalties LiabilityRelatedToFutureRoyalties	0	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	58006000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	59480000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30130000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30106000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	258000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	258000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	234230000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	138455000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61838565	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61701467	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	618000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	617000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1240345000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1235095000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	8000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-5000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1131703000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1093694000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	109268000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	142013000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	343498000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	280468000	usd
CY2023Q1	us-gaap	Revenues Revenues	24496000	usd
CY2022Q1	us-gaap	Revenues Revenues	11101000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	113000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	48000	usd
CY2023Q1	mgnx	Cost Of Manufacturing Services CostOfManufacturingServices	3410000	usd
CY2022Q1	mgnx	Cost Of Manufacturing Services CostOfManufacturingServices	0	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	45872000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	61438000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13527000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16253000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	62922000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	77739000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-38426000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-66638000	usd
CY2023Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1073000	usd
CY2022Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	195000	usd
CY2023Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	656000	usd
CY2022Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-38009000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-66443000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	13000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-222000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37996000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-66665000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.61
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.61
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.08
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.08
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61809817	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61809817	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61324163	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61324163	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	142013000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4788000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	617000	usd
CY2023Q1	mgnx	Stock Issued During Period Value Stock Plan Activity StockIssuedDuringPeriodValueStockPlanActivity	-154000	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	13000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-38009000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	109268000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	239618000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5224000	usd
CY2022Q1	mgnx	Stock Issued During Period Value Stock Plan Activity StockIssuedDuringPeriodValueStockPlanActivity	37000	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-222000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-66443000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	178214000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-38009000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-66443000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2983000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2913000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	372000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-334000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4833000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5274000	usd
CY2023Q1	mgnx	Non Cash Royalty Revenue NonCashRoyaltyRevenue	90000	usd
CY2022Q1	mgnx	Non Cash Royalty Revenue NonCashRoyaltyRevenue	0	usd
CY2023Q1	mgnx	Non Cash Interest Expense Recognized NonCashInterestExpenseRecognized	656000	usd
CY2022Q1	mgnx	Non Cash Interest Expense Recognized NonCashInterestExpenseRecognized	0	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-20062000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4520000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-42000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	210000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-443000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-6457000	usd
CY2023Q1	mgnx	Operating Lease Noncash Expense OperatingLeaseNoncashExpense	941000	usd
CY2022Q1	mgnx	Operating Lease Noncash Expense OperatingLeaseNoncashExpense	0	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-801000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-1148000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-11920000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-677000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-543000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-284000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1119000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2213000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	11280000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12833000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-57696000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	17296000	usd
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	54077000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	45750000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	37010000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	359000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1415000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	28095000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18482000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	616000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023Q1	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	5000	usd
CY2022Q1	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	37000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	158000	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2023Q1	mgnx	Net Proceeds From Sale Of Future Royalties NetProceedsFromSaleOfFutureRoyalties	99655000	usd
CY2022Q1	mgnx	Net Proceeds From Sale Of Future Royalties NetProceedsFromSaleOfFutureRoyalties	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	100118000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	37000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	115380000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-76141000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108884000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	123469000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	224264000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	47328000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	177000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	151000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	17384000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	8000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	17392000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	45467000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	11000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	45462000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	206000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	409000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1203000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1042000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	1409000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1451000	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	4900000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	4900000	usd
CY2022Q4	mgnx	Liability Related To Future Royalties LiabilityRelatedToFutureRoyalties	0	usd
CY2023Q1	mgnx	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	100000000	usd
CY2023Q1	mgnx	Deferred Transaction Costs DeferredTransactionCosts	-344000	usd
CY2023Q1	mgnx	Non Cash Royalty Revenue NonCashRoyaltyRevenue	90000	usd
CY2023Q1	mgnx	Non Cash Interest Expense Recognized NonCashInterestExpenseRecognized	656000	usd
CY2023Q1	mgnx	Liability Related To Future Royalties LiabilityRelatedToFutureRoyalties	100222000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q2	mgnx	Share Based Compensation Arrangement By Share Based Payment Award Offering Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod	P6M
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4833000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5274000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M17D
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10098929	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.58
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	2914405	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.89
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3531	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.51
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	87556	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.46
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	82635	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	22.01
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12839612	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.50
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M6D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7827000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7048779	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	20.90
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	660000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	11763189	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	16.03
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y10M24D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	6669000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.77
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.48
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	300000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	600000	usd
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	5400000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	29200000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
mgnx-20230331_pre.xml	Edgar Link	unprocessable
0001125345-23-000076-index-headers.html	Edgar Link	pending
0001125345-23-000076-index.html	Edgar Link	pending
0001125345-23-000076.txt	Edgar Link	pending
0001125345-23-000076-xbrl.zip	Edgar Link	pending
exhibit101driredactedagree.htm	Edgar Link	pending
exhibit31-1q12023.htm	Edgar Link	pending
exhibit31-2q12023.htm	Edgar Link	pending
exhibit32-1q12023.htm	Edgar Link	pending
exhibit32-2q12023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mgnx-20230331.htm	Edgar Link	pending
mgnx-20230331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
mgnx-20230331_cal.xml	Edgar Link	unprocessable
mgnx-20230331_def.xml	Edgar Link	unprocessable
mgnx-20230331_lab.xml	Edgar Link	unprocessable
mgnx-20230331_htm.xml	Edgar Link	completed
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MGNX
MACROGENICS INC Stock $mgnx

2023 Q2 Form 10-Q Financial Statement

#000112534523000076 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX MACROGENICS INC Stock $mgnx

2023 Q2 Form 10-Q Financial Statement

#000112534523000076 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX
MACROGENICS INC Stock $mgnx